Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016.. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell M1:1O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NED1SpJKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKDNwNk\lMVA2KM7:TR?= MnPaV2FPT0WU
CAL-51 cell M{jiXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3PGO2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjZibl2= NETKfZpUSU6JRWK=
ABC-1 cell NGjUOZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mk\aTY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y2KG6P NXHi[lBYW0GQR1XS
A2780 cell MlH1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? NWOwPGxsW0GQR1XS
ES1 cell MlPnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M37oZmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? NX\iNVViW0GQR1XS
HUTU-80 cell NFfj[GFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYnCWFA4UW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55OUGgcm0> MkfBV2FPT0WU
NCI-H292 cell NFjheYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYT0SY1NUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEi2JI5O MXTTRW5ITVJ?
NB69 cell M4S2SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NW\RRZVjUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOiCwTR?= MUDTRW5ITVJ?
ES8 cell M4H4PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2TrT2lvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zNkBvVQ>? M1;0WXNCVkeHUh?=
BCPAP cell MojoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkDWTY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Qhdk1? MnvpV2FPT0WU
T-24 cell NFPXUm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1JI5O M1HXSnNCVkeHUh?=
EW-16 cell NELVZpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1P0NmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyKG6P M{HHUHNCVkeHUh?=
OVCAR-5 cell NEG3XYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzx[2VZUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56MzDuUS=> MXLTRW5ITVJ?
SF126 cell NGTkbplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlzVTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVUhdk1? NEmyV4hUSU6JRWK=
KP-4 cell NV;O[JN6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NI\FXppKdmirYnn0bY9vKG:oIHj1cYFvKEuSLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlE4KG6P M2XDd3NCVkeHUh?=
GAMG cell NHTNZYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjCTY5pcWKrdHnvckBw\iCqdX3hckBISU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NUBvVQ>? MoHYV2FPT0WU
HOS cell NFrYenVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXnJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUOgcm0> NGe2WWFUSU6JRWK=
CHL-1 cell NXHHZoNKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUPJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj64NUBvVQ>? NHTufnZUSU6JRWK=
AGS cell NELYVJpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYrJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOE[gcm0> M1PiNXNCVkeHUh?=
MDA-MB-157 cell NVHJNI1DT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUf3TndPUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj65NkBvVQ>? Mor1V2FPT0WU
HSC-3 cell NWCwb5RJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYXLZZVpUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= MU\TRW5ITVJ?
CAL-72 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1zkOmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?= NF;RT3FUSU6JRWK=
NBsusSR cell MoT6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFvIOmhKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjF|IH7N MorzV2FPT0WU
ES7 cell NEjtZWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{HGS2lvcGmkaYTpc44hd2ZiaIXtZY4hTVN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61PUBvVQ>? NXjmSldSW0GQR1XS
H-EMC-SS cell NEjyeoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF:2PVVKdmirYnn0bY9vKG:oIHj1cYFvKEhvRV3DMXNUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=> M1HGVnNCVkeHUh?=
NCI-H1703 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVvjTYFuUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4ODNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[4JI5O M1\QSnNCVkeHUh?=
BHT-101 cell NHjFbJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWrxSW5jUW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55MjDuUS=> M1\yWnNCVkeHUh?=
SK-OV-3 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF3kWnJKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd3IH7N MWjTRW5ITVJ?
EW-24 cell NIPJcFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4OwbGlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg{KG6P MV3TRW5ITVJ?
PSN1 cell NGDxflBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVXJcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lki0JI5O Mk\aV2FPT0WU
OVCAR-8 cell NXPSU253T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NI\OdGNKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njl7IH7N M3fn[XNCVkeHUh?=
NCI-H1563 cell M3LPWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2DTcmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=> M3XyVHNCVkeHUh?=
SW756 cell MnXOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NU\OepdZUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2= MXLTRW5ITVJ?
A375 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFznO3BKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE1KG6P NIPBVYtUSU6JRWK=
Ca9-22 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmPPTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlI2KG6P MVfTRW5ITVJ?
SW1990 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkL4TY5pcWKrdHnvckBw\iCqdX3hckBUXzF7OUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlMzKG6P M2[z[nNCVkeHUh?=
ES4 cell M{HNbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFLlVm5KdmirYnn0bY9vKG:oIHj1cYFvKEWVNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|khdk1? NX7GPXVvW0GQR1XS
HCE-T cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV7mc3BRUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDVibl2= M3PjXHNCVkeHUh?=
MOLT-16 cell NGXPbHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoOyTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE42OyCwTR?= MV7TRW5ITVJ?
HSC-4 cell NE\uTm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVLJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND64JI5O NX\hOIU{W0GQR1XS
NCI-SNU-1 cell M{PvN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2fjO2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC56NjDuUS=> MnPqV2FPT0WU
EW-11 cell NFqxVIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NInaT2ZKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46KG6P NYf0WWs3W0GQR1XS
HT-1080 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2\h[2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlibl2= M4T0N3NCVkeHUh?=
MES-SA/Dx5 cells NEHXemVEgXSxdH;4bYNqfHliYYPzZZk> MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXMuW0FxRIi1JINmdGy|LDDJR|UxRTVibl2= M{fse|I{QTN5OUix
SW1710 cell NIPqN5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHPWeWNKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2= MljHV2FPT0WU
EW-1 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnvNTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yOEBvVQ>? MYDTRW5ITVJ?
BV-173 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIj6[lhKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzlibl2= MWrTRW5ITVJ?
TE-8 cell MnPnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkSxJI5O M2nFOXNCVkeHUh?=
G-401 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV\QSXpjUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2= NYrJWo9mW0GQR1XS
KOSC-2 cell MkL5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmLxTY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ2KG6P M33PcXNCVkeHUh?=
HuCCT1 cell NGHoNG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHexT5lKdmirYnn0bY9vKG:oIHj1cYFvKEi3Q1PUNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTJibl2= M3S4PXNCVkeHUh?=
FADU cell MkGxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHjnSFNKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P M2raVnNCVkeHUh?=
MHH-ES-1 cell NUTCcoRyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYXvbpM6UW6qaXLpeIlwdiCxZjDoeY1idiCPSFitSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkmgcm0> M{HiWnNCVkeHUh?=
ES3 cell NFrpRnZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGHBVnBKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|khdk1? NGjrcmFUSU6JRWK=
OVCAR-4 cell MkTpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV\4VmFnUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=> NF3MbYpUSU6JRWK=
HD-MY-Z cell MoXuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXzJcohq[mm2aX;uJI9nKGi3bXHuJGhFNU2\LWqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlkyKG6P NWXIZWpvW0GQR1XS
human JAR cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIXWNWdKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVchdk1? NF;OS5lUSU6JRWK=
A427 cell M2KySWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2ToXGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNFchdk1? NF7sT49USU6JRWK=
697 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwMUOgcm0> MXPTRW5ITVJ?
OVCAR-3 cell NHjlcnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVHJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIhdk1? MV;TRW5ITVJ?
human NB14 cell MmHZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14Lk[0JI5O M3[zeHNCVkeHUh?=
GB-1 cell Mo\aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{LDbWlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uO|Ehdk1? M2jPWXNCVkeHUh?=
COR-L105 cell M3nxNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWHJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44PiCwTR?= NG[5c4ZUSU6JRWK=
647-V cell NFzuNIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGG2[2ZKdmirYnn0bY9vKG:oIHj1cYFvKDZ2Nz3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46KG6P M2PYZ3NCVkeHUh?=
human K5 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGn5ZVBKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NzDuUS=> NF[zdHNUSU6JRWK=
DMS-273 cell M2naRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEnVT3hKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N MYfTRW5ITVJ?
UM-UC-3 cell MlHlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUfsRlNnUW6qaXLpeIlwdiCxZjDoeY1idiCXTT3VR{0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=> NICxeVJUSU6JRWK=
HEL cell Mlm2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF7KNZlKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNFghdk1? MojJV2FPT0WU
human KU-19-19 cell MknyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXHOPHNoUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEmgcm0> MVXTRW5ITVJ?
MC-IXC cell NFWye|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEDOUYtKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOTdibl2= NFPpfVJUSU6JRWK=
human H4 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml;xTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMkWgcm0> NEjD[2JUSU6JRWK=
NUGC-3 cell M3mwPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGjScYlKdmirYnn0bY9vKG:oIHj1cYFvKE6XR1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzNibl2= NUH4PI9QW0GQR1XS
CHP-212 cell MoqxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{HlR2lvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzRibl2= NILLcnFUSU6JRWK=
human SW982 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHnCXIlKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?= M3P5[HNCVkeHUh?=
C-33-A cell M3\OR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3[4PWlvcGmkaYTpc44hd2ZiaIXtZY4hSy1|Mz3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42QCCwTR?= NIfZZpBUSU6JRWK=
PC-3 cell NF32dphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4n5T2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFkhdk1? M1Gyd3NCVkeHUh?=
COLO-684 cell MmnhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4nLNmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjJzIH7N NECycVRUSU6JRWK=
SNU-387 cell NH7RRodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXLF[Yt7UW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtN|g4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS52OTDuUS=> NHrwWYRUSU6JRWK=
U251 cell NWnhNFJxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4ewbGlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFYhdk1? NH7henlUSU6JRWK=
A673 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUXJcohq[mm2aX;uJI9nKGi3bXHuJGE3PzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT62JI5O MYjTRW5ITVJ?
human T47D cell NWDYfIVYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1zvU2lvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG2Mlc6KG6P MW\TRW5ITVJ?
A549 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWS3W|dYUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPiCwTR?= MnPIV2FPT0WU
PC-14 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPFTY5pcWKrdHnvckBw\iCqdX3hckBRSy1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0Mlc{KG6P NXPaeI1mW0GQR1XS
A704 cell M4HWbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>? MUTTRW5ITVJ?
MCF7 cell M4PESGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFfRR2VKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{PiCwTR?= M4G0PXNCVkeHUh?=
PC3 cells NXKxTGhbTnWwY4Tpc44h[XO|YYm= M2S0N2lvcGmkaYTpc44hd2ZiUFTLNU1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQCC{ZYPp[JVmKGmwIHj1cYFvKFCFMzDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjFzMzFOwG0> MlTvNlE{PDF4N{W=
F-36P cells NIHR[YdRem:uaX\ldoF1cW:wIHHzd4F6 NG\kXIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF[tN|ZRKGOnbHzzMEBKSzVyPUCuNlgh|ryP MmL3NlE{PDF4N{W=
OCI-AML2 cells M{HnZ3Bzd2yrZnXyZZRqd25iYYPzZZk> MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN|Uh|ryP MX2yNVM1OTZ5NR?=
K562 cells M1\Xb3Bzd2yrZnXyZZRqd25iYYPzZZk> NUnOWpR1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? MVyyNVM1OTZ5NR?=

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Unknown status Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID